These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 23720767)
1. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767 [TBL] [Abstract][Full Text] [Related]
2. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075 [TBL] [Abstract][Full Text] [Related]
3. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461 [TBL] [Abstract][Full Text] [Related]
4. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers. Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813 [TBL] [Abstract][Full Text] [Related]
5. Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by Iommelli F; De Rosa V; Terlizzi C; Monti M; Panico M; Fonti R; Del Vecchio S Clin Cancer Res; 2018 Jul; 24(13):3126-3136. PubMed ID: 29618618 [No Abstract] [Full Text] [Related]
6. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799 [TBL] [Abstract][Full Text] [Related]
7. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765 [TBL] [Abstract][Full Text] [Related]
8. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib. Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779 [TBL] [Abstract][Full Text] [Related]
9. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718 [TBL] [Abstract][Full Text] [Related]
10. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography. Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479 [TBL] [Abstract][Full Text] [Related]
11. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329 [TBL] [Abstract][Full Text] [Related]
12. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231 [TBL] [Abstract][Full Text] [Related]
13. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Zhang YW; Staal B; Essenburg C; Su Y; Kang L; West R; Kaufman D; Dekoning T; Eagleson B; Buchanan SG; Vande Woude GF Cancer Res; 2010 Sep; 70(17):6880-90. PubMed ID: 20643778 [TBL] [Abstract][Full Text] [Related]
14. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities. Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282 [TBL] [Abstract][Full Text] [Related]
15. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib. Rice JW; Veal JM; Barabasz A; Foley B; Fadden P; Scott A; Huang K; Steed P; Hall S Oncol Res; 2009; 18(5-6):229-42. PubMed ID: 20225761 [TBL] [Abstract][Full Text] [Related]
16. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Tang Z; Du R; Jiang S; Wu C; Barkauskas DS; Richey J; Molter J; Lam M; Flask C; Gerson S; Dowlati A; Liu L; Lee Z; Halmos B; Wang Y; Kern JA; Ma PC Br J Cancer; 2008 Sep; 99(6):911-22. PubMed ID: 19238632 [TBL] [Abstract][Full Text] [Related]
17. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121 [TBL] [Abstract][Full Text] [Related]
18. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964 [TBL] [Abstract][Full Text] [Related]
19. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914 [TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Lara MS; Holland WS; Chinn D; Burich RA; Lara PN; Gandara DR; Kelly K; Mack PC Clin Lung Cancer; 2017 May; 18(3):281-285. PubMed ID: 28038979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]